INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events

November 2023 | Volume 22 | Issue 11 | SF389716s4 | Copyright © November 2023


Published online October 31, 2023

Alana Deutsch MDa, Mario Lacouture MDb, Anneke Andriessen PhDc, Jennifer N Choi MDd, Alice Y Ho MDe, Beth N McLellan MDf, Edith Mitchell MDg, Jonathan S Leventhal MDa

aDepartment of Dermatology, Smilow Cancer Hospital at Yale, New Haven, CT
bDivision of Oncodermatology, Memorial Sloan Kettering Cancer Center, New York, NY
cRadboud UMC, Nijmegen and Andriessen Consultants, Malden, The Netherlands
dDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL
eDepartment of Radiation Oncology, Duke University School of Medicine, Durham, NC
fDepartment of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, NY
gDepartment of Medical Oncology, Center to Eliminate Cancer Disparities, Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA

DISCLOSURES

The authors disclosed receipt of the following financial support for the research, authorship, and manuscript publication. This work was supported by an unrestricted educational grant from La Roche-Posay US. All authors contributed to the development of this work and its review and agreed with its content. 

The authors acknowledge the valuable contribution of Thomas Eberlein (TE), Dermatologist and Allergist, who, together with AA performed the literature searches and grading of the evidence for this work. 

MEL has a consultant role with Johnson and Johnson, Novocure, Bicara, Janssen, Novartis, EMD Serono, AstraZeneca, Innovaderm, Deciphera, DFB, Azitra, Kintara, RBC/La Roche Posay, Trifecta, Varsona, Genetch, Loxo, Seattle Genetics, Lutris, OnQuality, Oncoderm, NCODA, Apricity. Dr. Lacouture also receives research funding from Lutris, Paxman, Novocure, J&J, US Biotest, OQL, Novartis and AZ is supported funded in part by the NIH/NCI Cancer Center Support Grant P30 CA008748. JNC receives clinical trial research funding from OnQuality and has served on advisory boards for Regeneron, Parexel/Rockefeller, and PraHealth Sciences. AYH receives research funding from Merck, Natera, Glaxo Smith Kline, The Breast Cancer Research Foundation, NIH, and Department of Defense and has served as a consultant for Astra Zeneca. BNM receives clinical trial research funding from OnQuality and Pfizer, and has served on advisory boards for La Roche Posay and Paula’s Choice. JL receives clinical trial research funding from OnQuality and Azitra, and has served on advisory boards for La Roche Posay and Sanofi Regeneron. AD, AA, and EM have no conflicts of interest to disclosure. 

REFERENCES

  1. American Cancer Society. Cancer Facts & Figures 2023. Atlanta: American Cancer Society 2023.
  2. Dine J, Gordon R, Shames Y, et al. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4:127-135.
  3. ASCO Answers: Cancer.Net. Understanding Immunotherapy. American Society of Clinical Oncology, 2021, www.cancer.net/sites/cancer.net/files/asco_answers_immunotherapy.pdf.
  4. Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3:e200423.
  5. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345-361.
  6. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44:158-176.
  7. Malviya N, Tattersall IW, Leventhal J, et al. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol. 2020;38:660-678.
  8. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31-39.
  9. Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2018;14:247-249. 
  10. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073-4126.
  11. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-1357.
  12. Tang SQ, Tang LL, Mao YP, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat. 2021;53:339-354. 
  13. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83:1255-1268.
  14. Kaul S, Kaffenberger BH, Choi JN. Cutaneous adverse reactions of anticancer agents. Dermatol Clin. 2019;37:555-568.
  15. Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018;154:1057-1061.
  16. Jacoby TV, Shah N, Asdourian MS, et al. Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition. J Am Acad Dermatol. 2023;88:711-714.
  17. Lacouture ME, Choi J, Ho A, et al. US Cutaneous Oncodermatology Management (USCOM): a practical algorithm. J Drugs Dermatol. 2021;20(supp):s3-s19.
  18. Leventhal J, Lacouture M, Andriessen A, et al. United States Cutaneous Oncodermatology Management (USCOM) II: a multidisciplinary-guided algorithm for the prevention and management of acute radiation dermatitis in cancer patients. J Drugs Dermatol. 2022;21:SF3585693-SF35856914.
  19. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med. 2010;51:421-424.
  20. Trevelyan EG, Robinson, N. Delphi methodology in health research: how to do it? Eur J Integ Med. 2015;7:423-428.
  21. Cancer Research Institute. Immunotherapy by Cancer Type. Immunotherapy in Depth. www. cancerresearch.org/what-is-immunotherapy. Accessed August 2, 2023. 
  22. Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12.
  23. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1i. N Engl J Med. 2017;377:2500-2501. 
  24. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
  25. Quach HT, Johnson DB, LeBoeuf NR, et al. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021;85:956-966.
  26. Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41:125-128.
  27. Gault A, Anderson AE, Plummer R, et al. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol. 2021;185:263-271.
  28. Rzepecki AK, Cheng H, McLellan BN. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. J Am Acad Dermatol. 2018;79:545-555.
  29. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25.
  30. Phillips GS, Freites-Martinez A, Wu J, et al. Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics. JAMA Dermatol. 2019;155:249-251.
  31. Wu J, Lacouture ME. Pruritus associated with targeted anticancer therapies and their management. Dermatol Clin. 2018;36:315-324.
  32. Tattersall IW, Leventhal JS. Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. Yale J Biol Med. 2020;93:123-132.
  33. Kwatra SG, Stander S, Kang H. PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist. N Engl J Med. 2018;379:1578-1579.
  34. Ito J, Fujimoto D, Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58-61.
  35. Hibler BP, Markova A. Treatment of severe cutaneous adverse reaction with tocilizumab. Br J Dermatol. 2020;183:785-787. 
  36. Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79:1081-1088.
  37. Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57:664-669.
  38. Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2016;2:442-444.
  39. Sharma P, Barnes M, Nabeel S, et al. Pembrolizumab-induced bullous pemphigoid treated with rituximab. JCO Oncol Pract. 2020;16:764-766.
  40. Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. Dermatol Online J. 2021;27.
  41. Elkrief A, Derosa L, Kroemer G, et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30:1572-1579.
  42. Coleman E, Ko C, Dai F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80:990-997.
  43. Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol. 2017;39:121-129.
  44. Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152:1128-1136.
  45. Fixsen E, Patel J, Selim MA, et al. Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine. Oncologist. 2019;24:e103-e5.
  46. Pousti BT, Jin A, Sklovar L, et al. Dupilumab for the treatment of lichen planus. Cutis. 2021;107:E8-E10.
  47. Ch'en PY, Song EJ. Lichen planus pemphigoides successfully treated with dupilumab. JAAD Case Rep. 2023;31:56-58.
  48. Kazemi S, Murphrey M, Hawkes JE. Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab. JAAD Case Rep. 2022;30:108-110.
  49. Toumi A, Molva M, Bergeret B, et al. Lichen planus in psoriatic patients treated with interleukin 17 inhibitors: two additional cases and a literature review. Eur J Dermatol. 2022;32:795-796.
  50. Niebel D, Wilsmann-Theis D, Wenzel J. Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. J Dermatol. 2020;47:397-401.
  51. Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31:e254-e257.
  52. Chia PL, John T. Severe psoriasis flare after anti-programmed death ligand 1 (PD-l1) therapy for metastatic Non-Small Cell Lung Cancer (NSCLC). J Immunother. 2016;39:202-204.
  53. Mayor Ibarguren A, Enrique EA, Diana PL, et al. Apremilast for immune checkpoint inhibitor-induced psoriasis: a case series. JAAD Case Rep. 2021;11:84-89.
  54. Benevides L, da Fonseca DM, Donate PB, et al. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 2015;75:3788-3799.
  55. Coffelt SB, Kersten K, Doornebal CW, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345-348.

AUTHOR CORRESPONDENCE

Jonathan Leventhal MD jonathan.leventhal@yale.edu
Close Menu